Denali Therapeutics Inc. Cash and Restricted Cash
Denali Therapeutics Inc. (DNLI) had Cash and Restricted Cash of $204.64 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $204.64M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $390.73M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $208.43M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $94.07M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $204.64M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $390.73M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $208.43M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $94.07M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $144.31M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $60.05M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $176.53M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $92.21M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $76.25M 10-Q · filed 2025-08-11 |
| 2024-03-31 | $62.15M 10-Q · filed 2025-05-06 |
| 2023-12-31 | $128.68M 10-K · filed 2026-02-26 |
| 2023-09-30 | $149.59M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $133.55M 10-Q · filed 2024-08-01 |
| 2023-03-31 | $69.63M 10-Q · filed 2024-05-07 |
| 2022-12-31 | $219.54M 10-K · filed 2026-02-26 |
| 2022-09-30 | $120.11M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $156.59M 10-Q · filed 2023-08-08 |
| 2022-03-31 | $106.45M 10-Q · filed 2023-05-08 |
| 2021-12-31 | $294.98M 10-K · filed 2025-02-27 |
| 2021-09-30 | $396.05M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $487.18M 10-Q · filed 2022-08-08 |
| 2021-03-31 | $436.82M 10-Q · filed 2022-05-05 |
| 2020-12-31 | $508.64M 10-K · filed 2024-02-28 |
| 2020-09-30 | $352.55M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $138.68M 10-Q · filed 2021-08-04 |
| 2020-03-31 | $209.04M 10-Q · filed 2021-05-05 |
| 2019-12-31 | $80.95M 10-K · filed 2023-02-27 |
| 2019-09-30 | $84.17M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $64.44M 10-Q · filed 2020-08-07 |
| 2019-03-31 | $41.16M 10-Q · filed 2020-05-07 |
| 2018-12-31 | $78.62M 10-K · filed 2022-02-28 |
| 2018-09-30 | $45.15M 10-Q · filed 2019-11-06 |
| 2018-06-30 | $34.59M 10-Q · filed 2019-08-06 |
| 2018-03-31 | $44.45M 10-Q · filed 2019-05-08 |
| 2017-12-31 | $218.91M 10-K · filed 2021-02-26 |
| 2017-09-30 | $36.80M 10-Q · filed 2018-11-08 |
| 2017-06-30 | $41.84M 10-Q · filed 2018-08-09 |
| 2017-03-31 | $37.29M 10-Q · filed 2018-05-11 |
| 2016-12-31 | $40.39M 10-K · filed 2020-02-27 |
| 2015-12-31 | $30.82M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |